INSR and cancer: Without post-translational NLG modification of the IGF1R at this site, IGF1R/IR HRs apparently fail to localize to the plasma membrane, thus preventing receptor-ligand binding and decreasing the efficacy of anti-IGF1R antibody-based cancer therapies.